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P U B L I S H E D B Y E L S E V I E R I N C .iMAILL E T T E R S T O T H E E D I T O R describe the feasibility, safety, and efﬁcacy of contrast echocar-
Safety and Feasibility of
Contrast Echocardiography
for LVAD Evaluation
Transthoracic echocardiography (TTE) is an important tool for
the evaluation of cardiac and device function in left ventricular
assist device (LVAD)–supported patients. Echocardiographic
imaging may be technically challenging in some LVAD patients
because the position of the device and its inﬂow and outﬂow
cannula may obscure standard acoustic imaging windows.
Ventricular cavity opaciﬁcation using ultrasound contrast agents
enhances endocardial border detection and improves assessment
of chamber dimensions and systolic function (1); however, to
date, only a single case report describes the use of a contrast
agent in an LVAD patient (2). The purpose of this report is toFigure 1. CE Images of LVAD-Supported Patients With Technically Difﬁcul
Contrast echocardiography (CE) images before (A) and after (B) administration
border deﬁnition in a left ventricular assist device (LVAD) patient. CE aids ident
demonstrated by images acquired before (C) and after (D) contrast administratio
after (F) contrast administration demonstrate identiﬁcation of an apical thromb
LV ¼ left ventricle; RV ¼ right ventricle.diography (CE) in LVAD patients from a single-center
experience.
We retrospectively reviewed the records of patients with an
implantation of an LVAD followed at our center between
November 2005 and April 2013. Patients who received an ul-
trasound contrast agent during clinically indicated TTE were
identiﬁed. Commercially available contrast agents were used
during the study period: Optison (General Electric Healthcare,
Princeton, New Jersey) or Deﬁnity (Lantheus Medical Imaging,
Billerica, Massachusetts). CE was performed in accordance with
American Society of Echocardiography guidelines, using the
same protocol as that used for non-LVAD patients (1). Ac-
cording to our echocardiography laboratory’s CE clinical pro-
tocol, the efﬁcacy of CE for aiding image interpretation was
reported by the interpreting echocardiologist at the time of CE
as the following: aided image interpretation, worsened image
interpretation, or did not change image interpretation.t Noncontrast Images
of ultrasound contrast demonstrating improved left ventricular endocardial
iﬁcation of right ventricular enlargement in a different LVAD patient, as
n. In a third LVAD patient, focused left ventricular apical images before (E) and
us adjacent to the LVAD inﬂow cannula. Please see Online Video 1.
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430During the study period, a total of 2,323 TTE studies were
performed in 251 LVAD patients. Of them, 10 patients (4.0%)
underwent a total of 12 CE studies (0.5%) (2 patients had repeat
CE examinations). All patients underwent CE due to suboptimal
endocardial border deﬁnition during noncontrast TTE. All but
1 patient was supported by a HeartMate II (Thoratec Corporation,
Pleasanton, California) continuous-ﬂow LVAD, and this patient
was supported by a HeartMate XVE (Thoratec Corporation)
pulsatile-ﬂow LVAD. CE was performed successfully in all patients.
Deﬁnity contrast was used in 9 CE examinations, and Optison was
used in 3. Representative 2-dimensional echocardiography images
before and after contrast administration are shown in Figure 1. The
use of contrast aided image interpretation in 10 CE examinations
(83%) and did not change image interpretation in 2 (17%). CE
contributed to a change in LVAD patient management in 5 ex-
aminations (42%), including adjustment of pump speed in 3 pa-
tients, intensiﬁcation of inotrope support in 1 patient after
identiﬁcation of severe right ventricular systolic dysfunction, and
intensiﬁcation of anticoagulation therapy in 1 patient after identi-
ﬁcation of a previously unrecognized nonobstructive left ventricular
apical thrombus adjacent to the LVAD inﬂow cannula (Fig. 1,
Online Video 1). No adverse events or known side effects of ul-
trasound contrast agents were reported during or after CE in any
patient. Importantly, no changes in device function parameters were
noted during or after CE.
To our knowledge, this is the ﬁrst report to describe the use of
CE in multiple LVAD patients. CE was successfully performed
using a standard imaging protocol used for non-LVAD patients.
Uncertainty regarding both the risk of causing adverse reactions or
device function interference and the feasibility of diagnostic image
acquisition during continuous blood ﬂow into the device cannula has
likely led to a signiﬁcant underuse of CE in this population. Even at
our institution, CE was used in only 0.5% of TTE studies per-
formed on LVAD patients, although it is likely that many more
would have beneﬁted from its use. By comparison, CE is used in
w5% of all resting TTE studies in our laboratory. In summary, CE
was feasible and safe and improved image interpretation in a small
sample of LVAD patients undergoing clinically indicated echocar-
diography. CE should be used as needed during the echocardio-
graphic evaluation of LVAD patients with technically difﬁcult
images.
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Ex Vivo Cryoimaging for
Plaque Characterization
Histopathology is the gold standard for the validation of arterial
plaque characterization by in vivo methods. Volumetric comparison
of images with histopathology, however, can be cumbersome and
cost prohibitive. Cryoimaging provides real-time, ultra-high-reso-
lution anatomical bright-ﬁeld and ﬂuorescence data by alternatively
sectioning and imaging a tissue block face (1,2). Plaque morphology
is minimally altered, permitting precise volumetric tissue charac-
terization. Fibrous cap inﬂammation and elastin are important
biomarkers that correlate with plaque stability. With accurate
characterization of these constituents, cryoimaging can detect a
volumetric plaque transition to a vulnerable state.
We sought to characterize ﬁbrous cap inﬂammation and elastin in
coronary plaques by cryoimaging. We also introduce a method for
the use of cryoimaging as an adjuvant for plaque validation through
a single-case volumetric comparison of cross-sections from intra-
vascular optical coherence tomography (OCT) with cryoimaging
and histopathology.
A total of 18 atherosclerotic plaques were evaluated from 10 cor-
onary arteries of male cadavers (mean age 50.2  6.2 years). Vessels
were explanted and stored at 4C no longer than 48 h. A vessel was
ﬁxed to a plastic cylindrical rig and infused with optimal cutting
temperature gel. The optical coherence tomographic imaging cath-
eter was inserted through the ostial end of the vessel, and images
were captured every 200 mm by an automated 10 mm/s pull-back.
Images were screened for ﬁbroatheromatous and ﬁbrous segments
using consensus criteria (3). The start and end frames for plaque were
bookmarked for analysis by cryoimaging. The vessel was sectioned
into 5-cm cylindrical blocks and stored at 80C. Cryoimaging was
executed as previously described (2). Images were acquired in 5-mm
intervals until reaching the plaque of interest. A 3-mm slab was
sectioned and saved for histological analysis. Slabs were frozen
(n ¼ 7) or ﬁxed in 10% formalin and embedded in parafﬁn (n ¼ 11).
Slices were sectioned 7 mm thick and stained. Cryoimaging was
restarted until another plaque was reached or the vessel terminated.
Slides were digitally scanned and reviewed by 1 pathologist
(N.P.Z.). Fibrous caps were stratiﬁed into inﬂamed or noninﬂamed
groups on the basis of 2 thresholds for percent of capsule occupied
by macrophage (0% and 10%). Images from cryoimaging were split
into color channels, and mean intensity was measured over the
ﬁbrous cap pixel area. Univariate and multivariate logistic regression
with stepwise selection were performed. Odds ratios and areas under
the receiver operating characteristic curves were calculated. A p value
<0.05 was considered statistically signiﬁcant.
Methods and representative images from OCT, cryoimaging,
and histopathology are provided in Figure 1. A total of 3,246 optical
coherence tomographic frames, 22,864 cryoimaging frames, and 126
histological slides were evaluated. OCT accurately screened 81%
